Epidemiology od HAP
Otherno intervention
NCT Number: NCT02779933
A retrospective, observational study compiled data from all consecutively admitted patients older than 18 years at ICU University Hospital in Olomouc in the period from 1 January 2011 to 31 December 2015 who fulfilled the criteria of HAP. The aim was to determine the severity of the specific risk factors of early and late HAP. Risk factors were divided into factors from the patient and from the hospitalization. Furthermore, an assessment of their relationship to mortality.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
The primary outcome was to evaluate the relationship between risk factors and the development of early/late onset HAP. Another outcome was assessed to evaluate the relation of risk factors early/late onset HAP and mortality. The crucial time for evaluating the presence of risk factors was their presence from hospital admission to the moment of fulfilling the criteria for pneumonia. Risk factors were divided into two groups, on factors of the patient (uncontrollable) and by the hospitalization (controllable). Factors of the patient were: gender (male/female), age at enrollment (years), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, multi-organ failure presence (MOF), hypertension, ischemic heart disease (IHD) chronic renal insufficiency (CRI), continual use of renal replacement therapy (CRRT), acute renal insufficiency (ARI), diabetes mellitus (DM), Chronical Obstructive Pulmonary Disease (COPD), immunosuppression or leukopenia <1.5x109/l, impaired consciousness with Glasgow coma scale (GCS) <8 tracheotomy, head trauma/neurosurgery, abdominal surgery-thoracotomy. Side factors hospitalization were: aspiration into the lungs, urgent intubation, reintubated, sedation, bronchoscopy, nasogastric intubation, enteral feeding continuously/intermittently intolerance of enteral nutrition, physiotherapy, repeated transport of the patient from the ICU, length of hospital stay, length of mechanical ventilation, 30-day mortality.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
no intervention
Time frame: 30 days
Yes/No assessment
Time frame: 7 days
Assessment if mechanical ventilation was provided, or for how long
Time frame: 7 days
Assessment if hospital stay was present, or for how long
Time frame: 30 days
Assessment if repeated transports were present or not
Time frame: 7 days
Assessment if physiotherapy was provided or not
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
Time frame: 7 days
Yes/No assessment
University Hospital Olomouc
Other
Epidemiology of Risk Factors for Hospital-acquired Pneumonia in ICU Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04700202
Cross Infection, Disease Attributes
Dallas, Texas, United States
View Trial DetailsNCT05589727
Cross Infection, Disease Attributes
Barbalha, Ceará, Brazil
View Trial DetailsNCT04882085
Acute Pyelonephritis, Bacteremia
Bengbu, Anhui, China
View Trial DetailsNCT03348579
Cross Infection, Disease Attributes
Nantes, France
View Trial Details